Author:
Goonewardene Sanchia S.,Ventii Karen,Bahl Amit,Persad Raj,Motiwala Hanif,Albala David
Publisher
Springer International Publishing
Reference18 articles.
1. Moher D, Liberati A, Tetzlaff J, Altman DG. “Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The Prisma Statement.” [In English]. BMJ (Online) 339, no. 7716 (08 Aug 2009):332–36.
2. Mays N, Pope C, Popay J. “Systematically Reviewing Qualitative and Quantitative Evidence to Inform Management and Policy-Making in the Health Field.” [In English]. Journal of Health Services Research and Policy 10, no. SUPPL. 1 (July 2005):6–20.
3. D’Rummo KA, TenNapel MJ, Shen X. The impact of radiotherapy facility volume on the survival and guideline concordance of patients with muscle-invasive bladder cancer receiving bladder-preservation therapy. Am J Clin Oncol. 2019;42(9):705–10.
4. Wang JF, Zhou XF, Fang DB, Wu ZM, Ding ZS, Chen X, Liu NB. [The effect of tri-modality therapy on the treatment of muscle-invasive bladder cancer]. Zhonghua Yi Xue Za Zhi. 2018;98(20):1614–6.
5. Lendínez-Cano G, Rico-López J, Moreno S, Fernández Parra E, González-Almeida C, Camacho Martínez E. Elective bladder-sparing treatment for muscle invasive bladder cancer. Actas Urol Esp. 2014;38(1):7–13.